STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3609 by analyst upside · 2026-06-27
AMRX
Amneal Pharmaceuticals, Inc.
Healthcare · Market Cap $5B · P/E 46.6x
ANALYST PRICE TARGET
+0.1%
implied upside to consensus target
Current Price $17.23
Consensus Target $17.25
Bull Target $19.0
Bear Target $16.0
Analysts Covering 4
ANALYST CONSENSUS - STRONG BUY
Strong Buy
2
Buy
2
Hold
0
Sell
0
52-Week Low $7.67
52-Week High $17.86
YTD Return +36.1%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) 46.6x
Forward P/E 15.3x
EPS (TTM) $0.37
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3.0B
Profit Margin 4.0%
52-WEEK RANGE
52-Week Low $7.67
52-Week High $17.86
Current Price $17.23
Bear Target $16.0
Bull Target $19.0
● Now $17.23 ● Target $17.25
TRADING DATA
Avg Volume 1.7M
YTD Return +36.1%
Analyst Count 4
Consensus Strong Buy
Upside to Target +0.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at $17.23 with a Wall Street consensus price target of $17.25, implying potential upside of 0.1% over the next 12 months. 4 analysts currently cover AMRX, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $16.0.

AMRX operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 36.1% year-to-date and is currently trading near the upper end of its 52-week range of $7.67 – $17.86.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Overweight → Overweight 2026-05-20 Building track record
UBS ● Initiated
Buy 2026-04-17 33% win rate (6 calls)
Truist Securities — Reiterated
Buy → Buy 2026-03-02 Building track record
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Piper Sandler reit
Overweight → Overweight 2025-10-31 14% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2025-09-16 43% win rate (7 calls)
Barclays — Reiterated
Overweight → Overweight 2025-03-03 Building track record
JP Morgan ↑ Upgrade
Neutral → Overweight 2025-02-24 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
12/30
Consensus clarity
27/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →